• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer genetics and cytogenetics >Therapy-related acute myeloid leukemia with t(2;11)(q37;q23) after treatment for osteosarcoma.
【24h】

Therapy-related acute myeloid leukemia with t(2;11)(q37;q23) after treatment for osteosarcoma.

机译：骨肉瘤治疗后与t（2; 11）（q37; q23）治疗相关的急性髓细胞性白血病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The survival rate for children with osteosarcoma (OS) has improved dramatically with the introduction of multiagent chemotherapy. As the number of pediatric cancer survivors increases, there is a concern about the development of secondary malignant neoplasms. Secondary acute myeloid leukemia (AML) has been rarely reported after treatment for OS. We describe a 14-year-old boy with OS of the left ileum who developed secondary AML 15 months after completion of treatment. Cytogenetic analysis of the leukemic cells demonstrated deletion 11q23, whereas fluorescence in situ hybridization revealed rearrangement of the MLL gene. Only the addition of the long-distance inverse polymerase chain reaction technique identified the SEPT2 as the MLL fusion partner resulting in t(2;11)(q37;q23) that was reported in a very few secondary AML cases. Because of the cryptic nature of MLL translocations that cannot be detected by conventional cytogenetics or may misinterpreted as deletion, additional molecular techniques are required to identify the precise translocation partner. Because long-distance inverse polymerase chain reaction is not available in most molecular laboratories, the true incidence of t(2;11)(q37;q23) and the involvement of SEPT2 as the MLL translocation partner could be more prevalent in secondary AML.
机译：随着多药化疗的引入，儿童骨肉瘤（OS）的生存率已大大提高。随着儿科癌症幸存者数量的增加，人们对继发性恶性肿瘤的发展感到担忧。接受OS治疗的继发性急性髓细胞白血病（AML）很少见。我们描述了一个14岁男孩，左回肠OS，在完成治疗15个月后发生了继发性AML。白血病细胞的细胞遗传学分析显示缺失11q23，而荧光原位杂交揭示了MLL基因的重排。仅添加了远距离反向聚合酶链反应技术，才将SEPT2识别为MLL融合伴侣，从而导致t（2; 11）（q37; q23），这在极少数继发性AML病例中得到了报道。由于MLL易位的隐秘性质无法通过常规细胞遗传学检测或可能被误解为缺失，因此需要其他分子技术来鉴定精确的易位伴侣。由于在大多数分子实验室中远距离逆聚合酶链反应尚不可用，因此t（2; 11）（q37; q23）的真实发生率以及SEPT2作为MLL易位伴侣的参与在继发性AML中可能更为普遍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号